Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners cut its Regeneron stake by 96.3% in the third quarter, selling 35,373 shares and retaining 1,365 shares worth approximately $1.04 million. Institutional investors and hedge funds still own 83.31% of the company.
• Regeneron insiders sold 8,093 shares worth about $6.5 million over the past three months, including sales by Director Kathryn Guarini and EVP Marion Mccourt under pre-arranged Rule 10b5-1 plans.
• The company reported stronger-than-expected quarterly results, with $14.29 in adjusted EPS and $4.29 billion in revenue, while analysts maintain a “Moderate Buy” consensus and an average price target of $845.21.

Curated Wealth Partners LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 96.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,365 shares of the biopharmaceutical company's stock after selling 35,373 shares during the quarter. Curated Wealth Partners LLC's holdings in Regeneron Pharmaceuticals were worth $1,035,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $26,000. Armstrong Advisory Group Inc. grew its stake in Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 28 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $29,000. Finally, Trust Co. of Vermont bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $29,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director directly owned 603 shares in the company, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares in the company, valued at $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock worth $6,506,845 over the last three months. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $796.34 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a twelve month low of $564.00 and a twelve month high of $859.34. The company has a market cap of $81.99 billion, a P/E ratio of 19.68, a P/E/G ratio of 1.35 and a beta of 0.16. The business has a fifty day simple moving average of $791.59 and a 200 day simple moving average of $721.30.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period last year, the firm posted $12.81 earnings per share. Regeneron Pharmaceuticals's revenue was up 16.7% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an "overweight" rating in a research report on Tuesday, October 6th. Evercore increased their price target on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. Royal Bank Of Canada increased their price target on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a "sector perform" rating in a research report on Thursday, October 8th. Weiss Ratings reissued a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Finally, Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $845.21.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: UBS upgraded Regeneron to “Buy” and raised its price target to $978 from $660, arguing that the market is underestimating the long-term opportunity for Dupixent. The new target implies substantial upside and is the clearest near-term catalyst for investor optimism. Tickerreport UBS upgrade article
• Positive Sentiment: A valuation analysis says Regeneron still appears below fair value after fresh trial data and renewed attention on its immunology alliance. The report suggests the company’s earnings power may not be fully reflected in its current valuation. Regeneron stock fair value article
• Positive Sentiment: Regeneron could benefit from having paid off its balance owed to Sanofi, which had reduced the revenue reported from their partnership. The change may improve the financial contribution from the collaboration going forward. Trefis Regeneron catalysts article
• Positive Sentiment: Analysts expect double-digit bottom-line growth in the upcoming third-quarter report, keeping earnings momentum and the company’s ability to exceed estimates in focus. Barchart Regeneron earnings preview
• Neutral Sentiment: A review of biotechnology-sector results included Regeneron among the companies investors are evaluating, but provided limited new company-specific information. Yahoo Finance biotechnology earnings review
• Negative Sentiment: Director Andrew Murphy sold 4,147 shares worth approximately $3.2 million under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance, it is a limited bearish signal, although it may weigh modestly on sentiment.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.